摘要
目的:观察阿德福韦酯(ADV)治疗慢性乙型肝炎与乙型肝炎肝硬化的疗效。方法:收集初治的慢性乙型肝炎42例(乙型肝炎组),乙型肝炎肝硬化34例(肝硬化组),均给予ADV 10mg,口服,1/d,治疗48周,观察两组治疗前后病毒学、血清学、生物化学指标、PTA、Child-Pugh积分、丙氨酸氨基转移酶(ALT)及肾功能变化情况。结果:1ADV治疗后,两组血清总胆红素(TBIL)、ALT明显降低,血清白蛋白(ALB)明显升高,组间ALT差异无统计学意义。2ADV治疗后两组乙型肝炎病毒(HBV)DNA水平较治疗前明显下降,组间差异均无统计学意义;治疗后Child-Pugh积分降低、PTA升高。3两组治疗后均未出现血清肌酐超过正常参考值。结论:ADV抗病毒治疗后,慢性乙型肝炎病毒学、生物化学改善与乙型肝炎肝硬化相似,治疗48周后未发现不良反应。
Objective:To evaluate the antiviral efficacy of adefovir in patients with chronic hepatitis B and hepatitis B virus-related cirrhosis.Methods:A total of 42 patients with chronic hepatitis B and 34 patients with hepatitis B virus-related cirrhosis were collected.All subjects had not received any nucleoside analogue therapy before and they received 10 mg of adefovir once daily for 48 weeks.Virological,serological,biochemical index,PTA,Child- Pugh scores,alanine aminotransferase(ALT)and renal function were observed before and after the therapy.Results:1 After therapy,total bilirubin and ALT decreased obviously while the serum albumin increased,but there was no significant difference in ALT between the two groups.2After therapy,the levels of HBV DNA and Child-Pugh scores decreased obviously while PTA increased,but there was no significant difference in HBV DNA between the two groups.3Serum creatinine of all patients were no more than the upper limit of normal reference in the two groups after therapy.Conclusion:The virological and biochemical improvement are similar in patients with chronic hepatitis B and hepatitis B virus-related cirrhosis after ADV therapy.No adverse effect was observed after therapy for 48 weeks.
出处
《西北国防医学杂志》
CAS
2016年第9期573-575,共3页
Medical Journal of National Defending Forces in Northwest China
关键词
慢性乙型肝炎
乙型肝炎肝硬化
阿德福韦酯
治疗
chronic hepatitis B. hepatitis B virus-related cirrhosis
adefovir
therapy
